Medikamentöse therapie des fibromyalgiesyndroms: Systematische übersicht und metaanalyse

Translated title of the contribution: Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline

C. Sommer, W. Häuser, R. Alten, F. Petzke, M. Späth, T. Tölle, N. Üçeyler, A. Winkelmann, E. Winter, K. J. Bär

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations


Background: The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF; registration number 041/004) was planned starting in March 2011. Materials and methods: The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy ("Deutsche Interdisziplinären Vereinigung für Schmerztherapie", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. The recommendations were based on level of evidence, efficacy (meta-analysis of the outcomes pain, sleep, fatigue and healthrelated quality of life), acceptability (total dropout rate), risks (adverse events) and applicability of treatment modal ities in the German health care system. The formulation and grading of recommendations was accomplished using a multi-step, formal consensus process. The guidelines were reviewed by the boards of the participating scientific medical societies. Results and conclusion: Amitriptyline and-in case of comorbid depressive disorder or generalized anxiety disorder-duloxetine are recommended. Off-label use of duloxetine and pregabalin can be considered in case of no comorbid mental disorder. Strong opioids are not recommended. The English full-text version of this article is available at SpringerLink (under "Supplemental").

Translated title of the contributionDrug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline
Original languageGerman
Pages (from-to)297-310
Number of pages14
Issue number3
StatePublished - Jun 2012


Dive into the research topics of 'Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline: Systematische übersicht und metaanalyse'. Together they form a unique fingerprint.

Cite this